Table 1.
Basic characteristics of 27 studies included in meta-analysis
| First author(y) | Conutry | Index | Patients | Material | Assay | Staining pattern | Cut-off | Number | PD-L1(+/-) TC, NO. | Positive(%) | survival analysis method | HR estimation | Quality assessment(score) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1Bellmunt, J. | USA | Protein | Bladder cancer. | TMA | IHC | Membrane | Percentage (≥5%) | 160 | 32/128 | 20 | MA | Reported | 8 |
| 2Huang, Y. | China | Gene | Bladder cancer. | datasets | Datasets IHC | NA | Median PD-L1 expression levels | 165 | 40/125 | 24.2 | MA | Reported | 7 |
| 3Boorjian, S. A. | USA | Protein | Bladder cancer. | FFPE | IHC | Membrane | Percentage (≥5%) | 314 | 39/275 | 12.4 | MA | Reported | 8 |
| 4 Wang, Y. | China | Protein | Bladder cancer. | TMA | IHC | Membrane/ cytoplasm | Percentage (≥10%) | 50 | 36/14 | 72 | MA | Reported | 8 |
| 5Le Goux, C. | France | Protein | Bladder cancer. | FFPE | IHC | Membrane | Percentage (≥1%) | 108 | 55/53 | 50.9 | NA | NA | 7 |
| 6Wu, C. T. | Taiwan | Protein | Bladder cancer. | TMA | IHC | NA | IRS scoring grade ≥2 | 120 | 58/62 | 48.3 | UA | Calculated | 8 |
| 7Inman, B. A. | USA | Protein | Bladder cancer. | FFPE | IHC | Membrane | Percentage (≥1%) | 280 | 77/203 | 27.5 | NA | NA | 6 |
| 8Wang, Y. H. | China | Protein | Bladder cancer. | TMA | IHC | Membrane | Percentage (≥10%) | 60 | 43/17 | 71.7 | NA | NA | 6 |
| 9Erlmeier.F | Germany | Protein | Bladder cancer. | FFPE | IHC | Membrane | Percentage (≥10%) | 64 | 19/45 | 29.7 | UA | Calculated | 6 |
| 10Faraj, S. F. | USA | Protein | Bladder cancer. | TMA | IHC | Membrane | Percentage (≥5%) | 56 | 10/46 | 17.9 | NA | NA | 8 |
| 11Liu, Z. H. | China | Protein | Bladder cancer. | FFPE | IHC | Membrane/ cytoplasm | Percentage (≥10%) | 55 | 31/24 | 56.4 | NA | NA | 6 |
| 12Noro, D. | Japan | Protein | Bladder cancer. | FFPE | IHC | Membrane | Percentage (≥5%) | 102 | 38/64 | 37.3 | UA | Calculated | 8 |
| 13Xylinas, E. | USA | Protein | Bladder cancer. | TMA | IHC | Membrane | Percentage (≥5%) | 302 | 76/226 | 25 | MA | Reported | 8 |
| 14Powles, T. | NA | Protein | Bladder cancer. | FFPE | IHC | NA | Percentage (≥5%) | 205 | 22/183 | 11 | NA | NA | 8 |
| 15Zhang, B. | China | Protein | UTUC | FFPE | IHC | Membrane | Percentage (≥5%) | 162 | 20/142 | 12.3 | MA | Reported | 8 |
| 16Rosenberg, J. E. | NA | Protein | Bladder, Renal pelvis, Ureter Urethra. | FFPE | IHC | Membrane | Percentage (≥5%) | 310 | 100/210 | 32.3 | UA | Calculated | 8 |
| 17Plimack, E. R. | USA and Israel | Protein | Bladder, Renal pelvis, Ureter, Urethra. | FFPE | IHC | Membrane | Percentage (≥1%) | 115 | 61/54 | 53 | NA | NA | 8 |
| 18Balar, A. V. | NA | Protein | Bladder, Renal pelvis, Ureter, Urethra. | FFPE | IHC | Membrane | Percentage (≥5%) | 119 | 32/87 | 26.9 | NA | Calculated | 8 |
| 19Apolo, A. B. | NA | Protein | Bladder, Renal pelvis, Ureter, Urethra. | FFPE | IHC | Membrane | Percentage (≥5%) Percentage | 37 | 13/24 | 35.1 | NA | Calculated | 8 |
| 20Sharma, P. | NA | Protein | Bladder, Renal pelvis, Ureter, Urethra. | FFPE | IHC | Membrane | (≥1%) | 265 | 122/143 | 46 | NA | Calculated | 8 |
| 21Sharma, P. | NA | Protein | Bladder, Renal pelvis. | FFPE | IHC | Membrane | Percentage (≥1%) | 67 | 25/42 | 37.3 | NA | NA | 7 |
| 22Massard, C. | NA | Protein | Bladder cancer. | FFPE | IHC | Membrane | Percentage (≥25%) | 61 | 40/21 | 65.6 | NA | NA | 8 |
| 23Powles, T. | NA | Protein | Urothelial carcinoma | FFPE | IHC | Membrane | Percentage (≥25%) | 177 | 98/79 | 55.3 | NA | Calculated | 8 |
| 24Krabbe, L.M. | NA | Protein | UTUC. | TMA | Membrane/ cytoplasm | Percentage (≥1%) | 423 | 111/312 | 26.2 | MA | Reported | 8 | |
| 25Skala, S.L. | USA | Protein | UTUC. | TMA | IHC | Membrane | Percentage (≥5%) | 149 | 35/114 | 23.5 | MA | Reported | 8 |
| 26Tretiakova, M. | USA | Protein | Urothelial carcinoma | TMA | IHC | Membrane | Composite score | 101 | 21/80 | 20.8 | UA | Reported | 7 |
| 27Pichler, R. | Austria | Protein | Urothelial carcinoma | FFPE | IHC | Membrane | Percentage (≥5%) | 61 | 16/61 | 26.2 | UA | Reported | 7 |
Abbreviations: IHC, immunohistochemistry; FFPE, formalin-fixed paraffin-embedded; TMA, tissue microarray; UA, univariate analysis; MA, multivariate analysis; NA, not available; TC, tumor cell; UTUC, urothelial carcinoma of the upper urinary tract.